Navigation Links
Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
Date:6/29/2010

itor, is currently in Phase 3 trials for advanced colorectal cancer and multiple myeloma, under SPA and Fast Track designation granted by the FDA for both indications. Perifosine has also been granted orphan-drug status by the FDA for multiple myeloma and has received a positive opinion for Orphan Medicinal Product designation from the European Medicines Agency (EMA) in this same indication. In addition, perifosine has received positive Scientific Advice from the EMA for both multiple myeloma and colorectal cancer programs.

Perifosine is also in a Phase 1 trial in pediatric patients, as well as in other Phase 1 and Phase 2 trials for several other tumor types.

Perifosine is licensed to Keryx, in the United States, Canada and Mexico. Aeterna Zentaris has also out-licensed perifosine to Handok in South Korea, while retaining rights for the rest of the world.

About Colorectal Cancer

According to the American Cancer Society, colorectal cancer is the third most common form of cancer diagnosed in the United States. It is estimated that in the U.S., over 146,000 people were diagnosed with some form of colorectal cancer with over 49,000 patients dying from colorectal cancer in 2009. Surgery is often the main treatment for early stage colorectal cancer. When colorectal cancer metastasizes (spreads to other parts of the body such as the liver) chemotherapy is commonly used. Treatment of patients with recurrent or advanced colorectal cancer depends on the location of the disease. Chemotherapy regimens (i.e. FOLFOX or FOLFIRI either with or without bevacizumab) have been shown to increase survival rates in patients with metastatic/advanced colorectal cancer. Currently, there are seven app
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
2. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
3. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
4. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
5. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
6. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
7. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
8. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
10. AEterna Zentaris Announces Appointment of New Board Member
11. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Brussels (PRWEB) December 22, 2014 The ... the global leader of technical training across the life ... Clinical Data Management (SCDM) to provide the organization's ... certification programs —providing access to the more than 350 ... SCDM members with 10% off when registering for a ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... have a bad rep—and rightly so. The ability of ... it a destructive scourge to animals and plants alike. ... of Maryland,s A. James Clark School of Engineering and ... Professor Reza Ghodssi, is turning the tables, harnessing and ...
... See video from Novartis at: ... 24-month data showing that Tasigna® (nilotinib) continues to ... patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid ... data, from the first Phase III comparison of ...
... medical technology developed by Integrated Medical Systems, Inc., has ... Human Services and the U.S. Treasury Department as a ... grant to off-set its development efforts. The Qualifying Therapeutic ... the Patient Protection and Affordable Care Act of 2010. ...
Cached Biology Technology:Bad Virus Put to Good Use: Breakthrough Batteries 2Bad Virus Put to Good Use: Breakthrough Batteries 3Bad Virus Put to Good Use: Breakthrough Batteries 4Bad Virus Put to Good Use: Breakthrough Batteries 5Bad Virus Put to Good Use: Breakthrough Batteries 6Integrated Medical Systems' Technology Recognized as Qualified Therapeutic Discovery 2
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... New York, NY (February 13, 2013) For consumers of the ... healthit may be hard to believe that there is such ... of salt. But Charles Zuker, PhD, and colleagues at ... high concentrations of salt (think seawater levels, not potato chips), ...
... Alberta study shows that busy beavers are helping Canada geese get ... nesting. Ponds in Alberta where beavers were active tended to ... better chance at reproductive success, according to the study, published recently ... to link beavers to early season nesting habits of Canada geese ...
... chemistry in romance-inspired classics like Mimi,s aria from La Bohme, ... and that young lady pining for her man with "O ... in ACS, Journal of Chemical Education , however, focuses ... that intertwines famous operatic plots. Joo Paulo Andr ...
Cached Biology News:Scientists discover how animals taste, and avoid, high salt concentrations 2Scientists discover how animals taste, and avoid, high salt concentrations 3
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
Homo sapiens MEP50 protein, mRNA...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Biology Products: